1. Clinical management of borderline ovarian tumors. Issue 7 (July 2010) Authors: Trillsch, F; Mahner, S; Ruetzel, JD; Harter, P; Ewald-Riegler, N; Jaenicke, F; du Bois, A Journal: Expert review of anticancer therapy Issue: Volume 10:Issue 7(2010) Page Start: 1115 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Dilution of molecular-pathologic gene signatures (MPG) by parameter unrelated to tumor biology (UTB) may prevent prediction of the resection status after debulking surgery in patients with advanced ovarian cancer. (1st November 2019) Authors: Heitz, F; Kommoss, S; Tourani, R; Grandelis, A; Uppendahl, L; Aliferis, C; Burges, A; Wang, C; Canzler, U; Wang, J; Belau, A; Prader, S; Hanker, L; Ma, S; Ataseven, B; Hilpert, F; Schneider, S; Sehouli, J; Kimmig, R; Kurzeder, C Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. EP1223 Fertility-sparing surgery in patients with borderline ovarian tumors and reproductive outcomes. (1st November 2019) Authors: Helmut, P; Harter, P; Ataseven, B; Heitz, F; Prader, S; Schneider, S; Heikaus, S; Traut, A; du Bois, A Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A47 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. EP869 Treatment of ovarian cancer in Germany from 2004–2016: results of a nationwide quality assurance program (QS Ovar). (1st November 2019) Authors: Harter, P; Pfisterer, J; Hilpert, F; Sehouli, J; Lamparter, C; Kerkmann, M; du Bois, A Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A471 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. (2nd May 2019) Authors: Colombo, N; Sessa, C; du Bois, A; Ledermann, J; McCluggage, W G; McNeish, I; Morice, P; Pignata, S; Ray-Coquard, I; Vergote, I; Baert, T; Belaroussi, I; Dashora, A; Olbrecht, S; Planchamp, F; Querleu, D Journal: Annals of oncology Issue: Volume 30:Number 5(2019) Page Start: 672 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. (2nd May 2019) Authors: Colombo, N; Sessa, C; du Bois, A; Ledermann, J; McCluggage, W G; McNeish, I; Morice, P; Pignata, S; Ray-Coquard, I; Vergote, I; Baert, T; Belaroussi, I; Dashora, A; Olbrecht, S; Planchamp, F; Querleu, D Journal: Annals of oncology Issue: Volume 30:Number 5(2019) Page Start: 672 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P133 Low anterior resection syndrome (LARS) in patients with epithelial ovarian cancer after primary debulking surgery. (1st November 2019) Authors: Kranawetter, M; Grimm, C; Ataseven, B; Schneider, S; Riss, S; Alesina, P; Prader, S; Walz, M; Harpain, F; Stift, A; Heitz, F; Reinthaller, A; Polterauer, S; Harter, P; du Bois, A Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A140 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P168 Influence of first-line treatment for epithelial ovarian cancer on the immune system. (1st November 2019) Authors: Baert, T; Landolfo, C; Ceusters, J; Thirion, G; Van Hoylandt, A; Verschuere, T; Van Rompuy, A-S; du Bois, A; Timmerman, D; Vergote, I; Coosemans, A Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A161 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P81 Higher detection rate of lynch syndrome in patients with endometrial cancer by assessment of mismatch repair deficiency. (1st November 2019) Authors: Pauly, N; du Bois, A; Harter, P; Prader, S; Rhiem, K; Schömig-Markiefka, B; Heikaus, S; Heitz, F; Schneider, S; Baert, T; Traut, A; Ehmann, S; Ataseven, B Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A103 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy. (18th December 2017) Authors: Friedlander, M; Rau, J; Lee, C K; Meier, W; Lesoin, A; Kim, J -W; Poveda, A; Buck, M; Scambia, G; Shimada, M; Hilpert, F; King, M T; Debruyne, P; Bologna, A; Malander, S; Monk, B J; Petru, E; Calvert, P; Herzog, T J; Barrett, C Journal: Annals of oncology Issue: Volume 29:Number 3(2018) Page Start: 737 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗